anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
A cream made from the herb Tribulus Terrestris L. The cream preparation is made by low temperature water/alcohol extraction of Tribulus Terrestris L. After water/alcohol extraction of the herb Tribulus Terrestris L the extract is concentrated with a vacuum evaporator and mixed with a cream to concentrations of about 5, 10, 15% based on raw starting material. A number of factors are critical in preparation of the Tribulus Terrestris L raw material. These include: time of harvesting, part of the herb used, specific geographic area in Bulgaria where the herb is gathered, method of harvesting, and low temperature drying. Adherence to these factors guarantees high steroidal saponin, sapogenin and sterol content of the raw material used for making the cream. The finished cream has very strong anti-bacterial, anti-inflammation, anti-virus, anti-herpes effect and has been found to be highly useful in treating vulvo-vaginitis, vulvo-hemorrhoids, varicose veins and acne with. In some cases it blocks cancer cells from growing. This product was also found to be very successful in suppository form for the treatment of vulvo-vaginal, vulvo-hemorrhoidal and colonic conditions.
The invention relates to a chicken coccidiosis prevention and treatment preparation, in particular to a preparation technology of a chicken Eimeria tenella egg yolk antibody targeted sustained release preparation so as to solve the prevention and treatment problems of chicken coccidiosis. The preparation technology of the chicken Eimeria tenella egg yolk antibody targeted sustained release preparation includes the steps of: preparation, separation and purification of a highly immunized egg yolk antibody (IgY), and preparation of a microcapsule. Preparation of the microcapsule has the reaction conditions that: the chitosan concentration is 0.05-0.8% (w/v), the concentration of CaCl2 is 0.5-1.5% (w/v), the concentration of sodium alginate is 1.0-3.0% (w/v), and the IgY and the sodium alginate are in a mass ratio of 1-4:8. The IgY microcapsule prepared by the technical scheme involved in the invention is a preventive medicine, and is also a therapeutic drug. The microcapsule prepared by the invention provides a very good example for antibiotic substitution therapy. And the determined technology can also be used to prepare IgY or IgG microcapsules of other pathogenic microorganisms, thus having promotional value, and being beneficial to sound development of the green and organic chicken raising industry.
A polymeric foam with continuous, open-cell pores containing living cells suitable for medical applications and methods for preparing these foams. The microporous foams are of controlled pore size that may be utilized in a variety of applications. In general, the foams are characterized in that the pores are continuous and open-celled. In preparing the foams, an organic polymer is melted and combined with a selected solid crystalline fugitive compound, that melts above about 25° C. and/or that sublimates at above about 25° C. or can be extracted, to produce a substantially isotropic solution. The solution is cooled under controlled conditions to produce a foam precursor containing the solidified fugitive composition dispersed through a matrix of the organic polymer. Crystals of fugitive composition are then removed by solvent extraction and/or sublimation, or a like process to produce microcellular foams having a continuous, open-cell structure. After removing the fugitive composition, living cells capable of producing biologically active products are added to the pores to produce a foam containing living cells.
Sensitive CYP3A4 Substrates

BRAFTOVI is a strong CYP3A4 inducer at steady-state. Concomitant use of BRAFTOVI may decrease the plasma concentrations of CYP3A4 substrates (including hormonal contraceptives), [see Clinical Pharmacology (12.3)], which may reduce the efficacy of these substrates. Avoid the coadministration of BRAFTOVI with CYP3A4 substrates for which a decrease in plasma concentration may lead to reduced efficacy of the substrate. If the coadministration cannot be avoided, see the CYP3A4 substrate product labeling for recommendations.

OATP1B1, OATP1B3, or BCRP Substrates

Coadministration of BRAFTOVI with OATP1B1, OATP1B3, or BCRP substrates can result in increased concentrations of the substrates, and may increase toxicity of these agents. When used in combination, monitor patients closely for signs and symptoms of increased exposure and consider adjusting the dose of these substrates [see Clinical Pharmacology (12.3)].
Drowsiness: Since drowsiness may occur with the use of Doxepin Hydrochloride Cream, 5%, patients should be warned of the possibility and cautioned against driving a car or operating dangerous machinery while using this drug. Patients should also be cautioned that their response to alcohol may be potentiated.

Sedating drugs may cause confusion and oversedation in the elderly; elderly patients generally should be observed closely for confusion and oversedation when started on Doxepin Hydrochloride Cream, 5%. (See PRECAUTIONS - Geriatric Use.)

Use under occlusion: Occlusive dressings may increase the absorption of most topical drugs; therefore, occlusive dressings should not be utilized with Doxepin Hydrochloride Cream, 5%.

Contact sensitization: Use of Doxepin Hydrochloride Cream, 5% can cause Type IV hypersensitivity reactions (contact sensitization) to doxepin.
The research team closely will be following the mindfulness meditation intervention, developed by Kabat-Zinn, Lipworth, and Burney (1985), which is a part of the mindfulness-based stress reduction program. Mindfulness meditation is including interventions such as yoga, body scan, walking meditation, and sitting meditations. In the present study, the researchers will prefer sitting meditation. In this context, the second co-author will want patients to sit up in the chair in an upright and comfortable position. The patients will focus on deep breathing and felled the breath flowing throughout their body during the interventions that will last for 20 min in each session.
Patients will have only clear liquids after a normal breakfast and lunch on the day before surgery and subsequently fasten for 7-9 hours prior to surgery. Patients will ingest first dose of 45 ml oral sodium phosphate (NaP) enema (BT ORAL SOLUSYON 45 ML®, Yenisehir Lab. Tic. San. Ltd. Sti, Turkey) at 4 p.m. and a second dose at 8 p.m. in the evening before the scheduled surgery.
The invention refers to the treatment of diseases with paf-acether antagonists and a procedure for determining their efficacy. According to its chemical structure paf-acether (platelet-activating factor) is 1-0-alkyl-2-acetyl-sn-glyceryl-3-phosphocholine in C.R. Acad. Sci., Paris, No. 289, 1979, p. 1037-1040. According to the invention for treating a disease caused by lipoproteins (normal or modified) an effective amount of at least one paf-acether antagonist is administered to a subject requiring said treatment, wherein the paf-acether antagonist is a hydrophilic or non-hydrophilic triazolothieno-diazepine or an analogue thereof, a Ginkgolide, a Ginkgolide mixture or a synthetic Ginkgolide derivative, or an analogue of the paf-acether or a mixture with/of these compounds.
People who become infected with a virus such as SARS-CoV-2 usually develop an immune response and produce antibodies against the virus. Antibodies are natural proteins made by the body's immune system that attack viruses and other germs. These antibodies are found in plasma, which is the yellow, clear part of the blood. There have been other studies using plasma to treat other types of viruses that showed some positive results. Human plasma containing antibodies to the SARS-CoV-2 virus is an option for prevention and treatment of COVID-19. This type of treatment, known as passive antibody therapy, could be rapidly available when there are sufficient numbers of people who have recovered from infection and can donate antibody-containing plasma. In contrast to vaccination strategies, which begin to provide protection weeks after administration, antibody-containing plasma would provide its protective benefits immediately. Additionally, passive antibody therapy may be the only way to provide immunity for some immunocompromised patients who do not respond to vaccines.

This research will evaluate the safety of administration of plasma containing antibodies to the SARS-CoV-2 virus (i.e., convalescent plasma). The research will also measure the level of anti-SARS-CoV-2 antibodies in patient's blood after the administration of the convalescent plasma.
PURPOSE:To obtain an anticoccidial agent capable of safely and effectively preventing and treating coccidiosis of various animals without causing manifestation of side effects, decrement, etc., of effects due to acquisition of tolerance to medicines and maintaining a growth state well even in infection with the coccidiosis. CONSTITUTION:An anticoccidial agent having high safety is obtained by blending raw soybeans and Dichorae Radix normally at 1:(0.01-1) weight ratio of the raw soybeans:Dichorae Radix. The resultant anticoccidial agent can be used for both prevention and treatment. The dose thereof is normally about 0.5-8g/kg body weight/day raw soybeans and about 0.01mg to 1g/kg body weight/day Dichorae Radix expressed in terms of dry raw soybean powder and dry Dichorae Radix parent chemical powder in the case of oral administration and preferably administered for several to tens of days. In the case of the parenteral administration, the dose is preferably about 1/10 of that in the oral administration. Furthermore, even if the raw soybeans and Dichorae Radix are administered in the former period of the administration period and only the raw soybeans are administered in the latter period, effects are not deteriorated so much and the administration method is effective. Since the amount of the expensive Dichorae Radix can be reduced, the aforementioned administration method is economical.
theapplicationdisclosesapancreaticcancerearlydiagnosismarkerJAM-Aandapplicationthereofinanticancerdrugs. The ability of malignant cancer cells to proliferate abnormally and migrate high and invade can result in increased malignancy, poorer prognosis and decreased survival of the patient's tumor. How to prevent the deterioration of tumor cells or early lesions of tumors with low malignancy and to achieve accurate diagnosis and treatment at early stage also requires more new biomarkers and therapeutic targets. The connective adhesion molecule JAMA in the application is up-regulated in pancreatic inflammation tissues, early tumor precursor lesions and cancer tissues relative to normal tissues. The present application provides the effect of JAMA on the biological function of cancer cells. The JAMA can reduce proliferation and migration of cancer cells after knocking down, thereby further weakening the malignant behavior of the cancer cells. JAMA can be used as a new tumor biomarker and a prognosis marker, and provides effective information for cancer metastasis diagnosis, prognosis evaluation and treatment effect monitoring.
The antibody-coupled T cell receptor (ACTR) platform is an autologous engineered T cell therapy combining the cell-killing ability of T cells and the tumor-targeting ability of coadministered antibodies. Activation of the T cell product ACTR707 is dependent on the engagement of antibody bound to target cells via the CD16 domain of the chimeric receptor (CD16V-CD28-CD3ζ). ACTR707 in combination with the anti-CD20 monoclonal antibody rituximab was evaluated in the ATTCK-20-03 study, a multisite, single-arm, open-label phase I trial in B cell non-Hodgkin lymphoma (NHL). The primary objectives of this study were to evaluate the safety of the combination of ACTR707 and rituximab and to determine a recommended phase 2 dose (RP2D). Secondary objectives included evaluation of antitumor activity and ACTR T cell persistence. The study design included an ACTR707 cell dose escalation phase and an expansion phase at the RP2D. Escalating dose levels of ACTR707 in combination with rituximab were explored in 5 dose cohorts, with 25 subjects receiving study treatment. Subjects received lymphodepleting chemotherapy (cyclophosphamide 400 mg/m2/day and fludarabine 30 mg/m2/day) for 3 days, followed by rituximab 375 mg/m2 and, 24 to 48 hours later, a single dose of ACTR707. Additional doses of rituximab were administered every 3 weeks until disease progression, unacceptable toxicity, or investigator decision. Blood samples were collected at various time points to assess levels of rituximab, cytokines, inflammatory markers, and ACTR707 T cells. The overall response rate of ACTR707 plus rituximab was 56% (14 of 25) across all dose levels. Ten subjects (40.0%) achieved a complete response, with the longest duration of 586 days (range, 85 to 586 days), and 4 subjects (16.0%) experienced a partial response, with the longest duration of 130 days (range, 44 to 130 days). Only 1 case of cytokine release syndrome (grade 2) and no events of neurotoxicity were reported. There were no dose-limiting toxicities or events leading to death. ACTR707 plus rituximab resulted in only 1 adverse event (neutropenia), leading to study discontinuation of rituximab. The ATTCK-20-03 trial serves as proof of principle regarding the ACTR approach that potentially could be used with other antibodies targeting other markers in other malignancies. Although the ACTR707 program has been discontinued, these results may support other programs in the use of similar novel approaches of antibody-coupled T cell activation.
Patients with acute ST-segment elevation myocardial infarction who underwent Percutaneous coronary intervention (PCI) were treated with extracorporeal cardiac shock wave therapy 2-3 days after operation. The duration of treatment was 3 months, and 9 treatments were completed within 3 months as a course. One week of treatment was followed by a 3-week rest in each month. CSWT was performed three times in each treatment week, respectively on the 1st, 3rd, and 5th day of the treatment week, for a total of 3 months.
PROBLEM TO BE SOLVED: To obtain the subject agent useful for dealing with cerebral infarction characterized by the wetting and activation of leukocytes, in particular, monocytes/macrophages, by including, as active ingredient, a medicinal agent inhibiting the action of MCP-1 (Monocyte Chemotactic Protein-1). SOLUTION: This agent for dealing with cerebral infarction is obtained by formulating an active ingredient at 1-70 wt.% based on the whole composition. The active ingredient, which is a medicinal agent inhibiting the action of MCP-1, is as follows: (A) inhibiting the action of MCP-1 through binding thereto (e.g. an anti-MCP-1 neutralizing antibody such as human monoclonal antibody), (B) inhibiting the action of MCP-1 through acting on a MCP-1 receptor or MCP-1 receptor-holding cell (e.g. a MCP-1 receptor antagonistic agent), (C) a MCP-1 protein modifier, or (D) a prostaglandin having the inhibitory activity against cell migration induced by MCP-1. The daily dose of the active ingredient is pref. 0.01-1,000 mg/person.
Staphylococcus aureus is a prevalent pathogen in pneumonia and harbors glycolipids, which may serve as molecular patterns in Mincle (macrophage-inducible C-type lectin)-dependent pathogen recognition. We examined the role of Mincle in lung defense against S aureus in wild-type (WT), Mincle knockout (KO), and Mincle transgenic (tg) mice. Two glycolipids, glucosyl-diacylglycerol (Glc-DAG) and diglucosyl-diacylglycerol (Glc2-DAG), were purified, of which only Glc-DAG triggered Mincle reporter cell activation and professional phagocyte responses. Proteomic profiling revealed that Glc2-DAG blocked Glc-DAG-induced cytokine responses, thereby acting as inhibitor of Glc-DAG/Mincle signaling. WT mice responded to S aureus with a similar lung pathology as Mincle KO mice, most likely due to Glc2-DAG-dependent inhibition of Glc-DAG/Mincle signaling. In contrast, ectopic Mincle expression caused severe lung pathology in S aureus-infected mice, characterized by bacterial outgrowth and fatal pneumonia. Collectively, Glc2-DAG inhibits Glc-DAG/Mincle-dependent responses in WT mice, whereas sustained Mincle expression overrides Glc2-DAG-mediated inhibitory effects, conferring increased host susceptibility to S aureus.
Opioids are dispensed regularly to manage postoperative pain in patients undergoing surgery in hospitals and same day surgery centers. There has been a rise in the number of opioid misuse and overdoses nationally, with Ohio ranked first in the nation for drug overdose deaths in 2014 and Cuyahoga County leading the state with 666 overdose deaths in 2016(ref) As health care providers, it is our responsibility to respond to this epidemic. One measure to address this is to reduce the number of unused prescription opioids that remain in patients' possession when they no longer need them. (ref) Doing so will maximize safety by decreasing the availability of unused opioids. The purpose of this study is to determine if a product that deactivates opioids will be used as designed after oral opioid medication is no longer needed. The design of this study is a quality initiative project using a randomized control design. The setting is a surgery center in a suburban hospital in Cuyahoga County. The population is all adult surgery center patients that are prescribed opioids postoperatively who are discharged the same day. In addition to usual care, a medication disposal bag with instructions on how to use will be given to the patient prior to discharge. The patient will be called 30-45 days post discharge. The data will be collected on a case report form that will include information about disposal and information obtained from the patients medical record.
PURPOSE:To enable identification of the dentin and the dental enamel by constituting a material for identifying the tooth substance of a high polymer material having a carboxyl group, org. titanate comp. and pH indicator having a discoloration region in 2-7pH. CONSTITUTION:A material for idensifying the tooth substance layer is constituted of a high polymer material having a carboxyl group, org. titanate compd. and pH indicator having a discoloration region in 2-7pH. The reagent component reacts with the dentin and enables discrimination of the dentin and the dental enamel when the reagent consisting of such specific compsn. is used. A method for mixing the high polymer material having a carboxyl group, org. titanate compd. and pH indicator in the presence of an org. solvent is most adequately used as a method for mixing these materials. Ethanol, ethyl acetate or aceton is adequately used as the org. solvent as said solvent is genrally low in b.p. and is easily removable.
Enteric septicemia of catfish (ESC), caused by the gram-negative enteric bacteria Edwardsiella ictaluri, is a significant threat to catfish aquaculture in the southeastern United States. Antibiotic intervention can reduce mortality; however, antibiotic use results in an imbalance, or dysbiosis, of the gut microbiota, which may increase susceptibility of otherwise healthy fish to enteric infections. Herein, recovery of the intestinal microbiota and survivability of channel catfish in response to ESC challenge was evaluated following a 10-day course of florfenicol and subsequent probiotic or prebiotic supplementation. Following completion of florfenicol therapy, fish were transitioned to a basal diet or diets supplemented with a probiotic or prebiotic for the remainder of the study. Digesta was collected on Days 0, 4, 8 and 12, beginning on the first day after cessation of antibiotic treatment, and gut microbiota was characterized by Illumina sequencing of the 16S rRNA gene (V4 region). Remaining fish were challenged with E. ictaluri and monitored for 32 days post-challenge. Florfenicol administration resulted in dysbiosis characterized by inflated microbial diversity, which began to recover in terms of diversity and composition 4 days after cessation of florfenicol administration. Fish fed the probiotic diet had higher survival in response to ESC challenge than the prebiotic (p = .019) and negative control (p = .029) groups.
Participants will receive weekly Sham Shockwave Therapy (SWT) and Placebo Saline Intracavernosal Injection (ICI) for 5 weeks. Sham SWT will be administered weekly on Weeks 1, 2, 3, 4, and 5. Placebo Saline ICI will be administered on Week 1 and Week 5.
The patient shook his head horizontally and looked in the direction of head rotation. Repeated 10 times, and then shook his head with eyes closed and repeated 10 times. The patient holds a small visual target to practice. The small visual target is placed about 30cm in front of the patient. The subject moves his head back and forth while keeping his sight on the target. Besides, patients wear headphones to listen to the numbers at the same time. The numbers contain 1 and 2, and they are played randomly. They shake their heads when they hear 1, and nod when they hear 2. The training takes 30 minutes, once a day in the morning and evening.
Participants meeting eligibility criteria will participate in the Mind Body Program for Vascular Disease, working in-person or via telehealth with a study interventionist for an hour weekly in 6-8 week cycles learning problem-solving techniques targeting mood/distress and enhancing disease management strategies. Participants will be assessed at baseline, 3-months, and 6-months.
A portable, autonomous electronic device consisting of a barcode scanner, an updatable nutrition facts database, user memory to store product records of products eaten, and an integral readout display is disclosed that will allow a user to scan barcodes on food items consumed and keep a cumulative total of calories and other nutrients. Prepared packaged foods may have their barcodes read directly, while foods that are used in cooking or preparing other foods may be referenced by scanning from a printed generic foods barcode list provided with the device. Serving sizes can be adjusted to accurately reflect the intake of given food items. Daily cumulative totals of calories and several other nutrients can be displayed as bar graphs, and the incremental increase that would result from consuming a scanned item can be displayed with reference to what has already been consumed. Weekly calorie totals broken down by day can be displayed in order to give an estimation of how successfully the user has adhered to diet goals over a dietarily significant span of time. Barcode numbers of food items input into the device along with date and serving size consumed can be stored in user memory and downloaded to another device, for example a computer or printer, via an interface. Diet strategies can be personalized with respect to any one of or combination of several nutritional categories, such as calories, fat, etc.
PURPOSE:To provide a new compound useful as an intermediate for synthesizing a pyridonecarboxylic acid derivative having an excellent antimicrobial force. CONSTITUTION:The objective compound of formula I [R is H, lower alkyloxycarbonyl or (halogenated) acyl; m is 0, 2; n is 0, 1]. e.g. 6- trifluoroacetylamino-3-azabicyclo[3.2.0]octane. The compound of formula I is obtained by catalytically reducing a compound of formula II (Z is a reductively releasable protecting group) in the presence of a catalyst at 0-80 deg.C for 30min to 24hrs. The compound of formula I can be reacted with a known pyridonecarboxylic acid by a conventional method into a pyridonecarboxylic acid derivative useful as an antimicrobial agent.